Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective MGD compounds to meet unmet medical needs in all therapeutic areas.
Stay ahead of the competition with real-time market intelligence and actionable insights.
Disclaimer: All information contained in this database has been researched and compiled from many legitimate sources, believed to be accurate and reliable at the time of publishing. However, in view of the natural scope for human and/or mechanical error, either at source or during production, Dietary Business Intelligence (DBI) ( www.dbi360.com ) accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions affecting any part of the database. All information is provided without warranty, and DBI makes no representation of warranty of any kind as to the accuracy or completeness of any information hereto contained and strongly encourages that upon final material or product selection data points are validated with the supplier.
© Copyright 2026 Dietary Business Intelligence LLC. All Rights Reserved.
